exon skipping compound PRO051

A multinational pharmaceutical company has committed to developing Prosensa's exon skipping compound for DMD

posted on October 19, 2009 - 9:00pm
On Oct. 13, 2009, the multinational pharmaceutical company GlaxoSmithKline announced it will develop and commercialize the experimental “exon skipping” compound PRO051 for Duchenne muscular dystrophy (DMD). The commitment of a major pharmaceutical company to development of a drug for DMD is very good news for families with this disease.

New content is being added every day. Please check back again.